<50%
[link to www.washingtonexaminer.com (secure)]


'Clinical trials of the vaccine for shingles, a debilitating disease triggered by a chronic form of the virus that causes chickenpox, will begin in the second half of the year, according to an announcement from the companies (2022)."

"Infectious disease experts lauded the development of mRNA COVID-19 vaccines, which can be tailored in labs relatively easily to target specific pathogens. Because the mRNA is produced in a chemical process rather than a biological one, like the flu vaccine, mRNA production can be scaled up quickly to produce massive quantities of product, as seen during the massive vaccine rollout early last year."

Pfizer-BioNTech’s new vaccine would compete with GlaxoSmithKline's two-dose vaccine Shingrix, which was approved by the Food and Drug Administration in 2017.